Multidrug Resistance 1 Polymorphisms and Trough Concentrations of Atazanavir and Lopinavir in Patients with HIV
Authors:
- 27 February 2007
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 8 (3) , 227-235
Abstract
HIV-infected patients receiving protease inhibitors may benefit from therapeutic drug monitoring-assisted dose adjustment to achieve target plasma concentrations. However, efflux pumps such as permeability-glycoprotein, which is encoded by the multidrug resistance (MDR)1 gene, may decrease intracellular drug concentrations, thus reducing the amount of drug at the site of action. Plasma concentrations of protease inhibitors and CD4 cell count response have been associated with the T allele at the MDR1 C3435T locus. We examined MDR1 single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol. In a multicenter study, genotypic analyses at two MDR1 loci, C3435T and G2677T, were performed by a real-time polymerase chain reaction method using DNA from 103 patients categorized as substance users or nonusers on atazanavir or lopinavir as the primary antiretrovirals. Allelic frequencies were determined as a function of racial/ethnic background, substance use status and trough concentrations of atazanavir and lopinavir. The C/T and G/T alleles at the MDR1 C3435T and G2677T loci were equally frequent in the Caucasian population, but the wild-type alleles were more prevalent in the African-American population (59% homozygous [CC] and 32% heterozygous [CT] for C3435T; 80% homozygous [GG] and 16% heterozygous [GT] for G2677T). The frequencies in the Hispanic population were 46% CC and 38% CT for C3435T, and 58% GG and 38% GT for G2677T. No significant differences were seen in allele frequencies for MDR1 polymorphisms in substance user versus nonuser groups. Trough plasma concentrations of atazanavir or lopinavir were not correlated with the variant T allele. These data confirm the higher prevalence of wild-type alleles of the MDR1 gene in African-Americans and the linkage disequilibrium between C3435T and G2677T loci. The T allele at the MDR1 C3435T and G2677T loci was not associated with higher atazanavir or lopinavir trough concentrations.Keywords
Funding Information
- University of Miami AIDS Research Unit
- University Hospitals Case Medical Center HIV
- National Institute on Drug Abuse (DA-015024)
- Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center (AI-51519)
This publication has 34 references indexed in Scilit:
- Quality Assurance Program for Pharmacokinetic Assay of Antiretrovirals: ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories, 2003 to 2004Therapeutic Drug Monitoring, 2006
- Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patientsHIV Medicine, 2006
- Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitorsin vitroBasic & Clinical Pharmacology & Toxicology, 2006
- Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1Clinical Infectious Diseases, 2006
- Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2005
- Pharmacogenomics and HIV TherapeuticsThe Journal of Infectious Diseases, 2005
- P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and TherapyAntimicrobial Agents and Chemotherapy, 2004
- The role of clinical pharmacology in optimizing antiretroviral therapyBritish Journal of Clinical Pharmacology, 2003
- Lopinavir/RitonavirDrugs, 2003
- Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy responseAIDS, 2003